Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Malignant melanoma
- Focus Therapeutic Use
- 22 May 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 17 May 2019 Planned initiation date changed from 1 Dec 2018 to 1 Sep 2019.
- 06 Dec 2018 New trial record